natgillin/translations-raw huggingface dataset:
The most frequently (seen in ≥ 1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema. 
Najčešće zabilježene nuspojave (uočene u ≥1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glukozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
• Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn. 
- Shizofrenije, bolesti sa simptomima kao što su slušna, vidna ili osjetilna priviđenja stvari koje nisu prisutne, iluzije, neuobičajena sumnjičavost i povučenost.
Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (≥ 0.1% and < 1%). 
Vremenska povezanost liječenja olanzapinom i venske tromboembolije (VTE) zabilježena je manje često (<0,01% i < 1%).
If you suddenly stop taking Zalasta, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. 
Ako naglo prestanete s uzimanjem Zalaste mogu se pojaviti simptomi poput znojenja, nesanice, drhtanja, tjeskobe ili mučnine i povraćanja.
Patients treated with any antipsychotic medicines, including Zalasta, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter. 
U bolesnika liječenih bilo kojim antipsihotikom, uključujući Zalastu, potrebno je redovito pratiti razinu lipida prema smjernicama korištenih antipsihotika, na primjer, na početku liječenja, 12 tjedana nakon početka liječenja olanzapinom te svakih 5 godina nakon toga.
Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database. 
Nuspojava je identificirana iz spontanih prijava nakon stavljanja lijeka u promet, a učestalost je određena na gornjoj granici 95%-tnog intervala pouzdanosti uz pomoć integrirane baze podataka za olanzapin.
Zalasta contains the active substance olanzapine. 
Zalasta sadrži djelatnu tvar olanzapin.
Dystonia (including oculogyration) Tardive dyskinesia Amnesia 
Distonija (uključujući okulogiraciju) Tardivna diskinezija
Hyperglycaemia and/or development or exacerbation of diabetes occasionally associated with ketoacidosis or coma has been reported uncommonly, including some fatal cases (see section 4.8). 
Manje često su zabilježeni hiperglikemija i/ili razvoj ili egzacerbacija dijabetesa ponekad povezani s ketoacidozom ili komom, uključujući neke smrtne slučajeve (vidjeti dio 4.8).
Zalasta tablets contain lactose. 
Zalasta tablete sadrže laktozu.
In renally impaired patients (creatinine clearance < 10 ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0 l/hr). 
U bolesnika s oštećenjem funkcije bubrega (klirens kreatinina <10 ml/min) nije bilo značajne razlike u odnosu na zdrave ispitanike u prosječnom poluvremenu eliminacije (37,7 u odnosu na 32,4 sata) ili klirensu (21,2 u odnosu na 25,0 l/sat).
Olanzapine demonstrated a greater in vitro affinity for serotonin 5 HT2 than dopamine D2 receptors and greater 5 HT2 than D2 activity in vivo, models. 
Olanzapin je in vitro pokazao veći afinitet za serotoninske 5HT2 nego dopaminske D2 receptore te veće djelovanje na 5HT2 nego D2 u in vivo modelima.
In a single oral dose (10 mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5 HT2A than dopamine D2 receptor occupancy. 
U ispitivanju pomoću pozitronske emisijske tomografije (PET), jednostruka oralna doza (10 mg) olanzapina u zdravih dobrovoljaca dovela je do većeg zauzimanja 5HT2A nego dopaminskih D2 receptora.
Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 
Razvoj ili egzacerbacija dijabetesa ponekad povezano s ketoacidozom ili komom, uključujući i neke slučajeve sa smrtnim ishodom (vidjeti dio 4.4)
There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs. 0.4%, respectively). 
U bolesnika liječenim olanzapinom zabilježen je trostruki porast CVAE-a u usporedbi s bolesnicima koji su liječeni placebom (1,3% u odnosu na 0,4%).
Neuroleptic malignant syndrome (see section 4.4) Discontinuation symptoms 
Neuroleptički maligni sindrom (vidjeti dio 4.4)
Zalasta contains aspartame 
Zalasta sadrži aspartam
See section 2 "Zalasta contains lactose". 
Vidjeti dio 2. „Zalasta sadrži laktozu“.
Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline. 
Prosječni porast vrijednosti lipida natašte (ukupni kolesterol, LDL kolesterol i trigliceridi) bio je veći u bolesnika bez dokazane disregulacije lipida na početku.
With long-term exposure (at least 24 weeks), 89.4 % gained ≥ 7 %, 55.3 % gained ≥ 15 % and 29.1 % gained ≥ 25% of their baseline body weight. 
Tijekom dugotrajne izloženosti (najmanje 24 tjedna), u 89,4% bolesnika povećala se tjelesna težina ≥ 7%, u 55,3% ≥ 15%, a u 29,1% bolesnika tjelesna težina se povećala ≥ 25% od njihove tjelesne težine na početku liječenja.
Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of druginduced bone marrow depression/toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease. 
Oprez je potreban u bolesnika s niskim brojem leukocita i/ili neutrofila iz bilo kojeg razloga, u bolesnika koji primaju lijekove za koje se zna da uzrokuju neutropeniju, u bolesnika s anamnezom depresije/toksičnosti koštane srži uzrokovane lijekovima, u bolesnika s depresijom koštane srži uzrokovane komorbiditetnom bolesti, zračenjem ili kemoterapijom te u bolesnika s hipereozinofilnim stanjima ili mijeloproliferativnom bolesti.
Increased alkaline phosphatase High creatine phosphokinase High Gamma Glutamyltransferase High uric acid 
Povišena alkalna fosfataza Visoka kreatin fosfokinaza Visoka gama glutamiltransfer aza
Metabolism and nutrition disorders Weight gain 
Poremećaji metabolizma i prehrane Povećanje tjelesne težine
In cytopenic dogs, there were no adverse effects on progenitor and proliferating cells in the bone marrow. 
U pasa s citopenijom nije bilo nuspojava na matičnim i proliferacijskim stanicama koštane srži.
Seizures where in most cases a history of seizures or risk factors for seizures were reported 
Napadaji u većini slučajeva kada su zabilježeni napadaji u anamnezi ili čimbenici rizika za nastanak napadaja
In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D2 occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients. 
Osim toga, ispitivanje jednofotonskom emisijskom računalnom tomografijom (SPECT, engl. single photon emission computed tomography) snimanja u bolesnika sa shizofrenijom otkrila su da bolesnici koji reagiraju na olanzapin imaju manju zauzetost strijatalnih D2 receptora od bolesnika koji su reagirali na neke druge antipsihotike i risperidon, dok je zauzetost bila usporediva s onom u bolesnika koji su reagirali na klozapin.
In a second 12-month recurrence prevention study in manic episode patients who achieved remission with a combination of olanzapine and lithium and were then randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0%, lithium 38.3%; p=0.055). 
U drugom 12-mjesečnom ispitivanju prevencije relapsa epizode manije, bolesnici koji su postigli remisiju kombinacijom olanzapina i litija te su potom bili randomizirani u skupinu koja je primala samo olanzapin ili samo litij, olanzapin nije bio statistički inferioran litiju u pogledu primarnog ishoda relapsa bipolarnog poremećaja (olanzapin 30,0%, litij 38,3%; p=0,055).
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly. 
Akutni simptomi kao što su znojenje, nesanica, tremor, anksioznost, mučnina i povraćanje zabilježeni su prilikom naglog prekida primjene olanzapina.
Blood and the lymphatic system disorders Eosinophilia 
Poremećaji krvi i limfnog sustava Eozinofilija
─ Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. 
- Vrlo rijetko, lijekovi ovog tipa uzrokuju kombinaciju vrućice, ubrzanog disanja, znojenja,
It has the same dosage and frequency of administration as olanzapine tablets. 
Ima isto doziranje i učestalost primjene kao tablete olanzapina.
As it exhibits in vitro dopamine antagonism, olanzapine may antagonize the effects of direct and indirect dopamine agonists. 
S obzirom da olanzapin in vitro pokazuje antagonizam s dopaminom, on može imati antagonističke učinke na izravne ili neizravne agoniste dopamina.
7 tablets 14 tablets 28 tablets 35 tablets 56 tablets 70 tablets 
7 tableta 14 tableta 28 tableta 35 tableta 56 tableta 70 tableta
See package leaflet for further information. 
Vidjeti uputu o lijeku za detaljnije informacije.
Repeated-dose toxicity 
Toksičnost ponavljane doze
14 tablets 28 tablets 35 tablets 56 tablets 70 tablets 
14 tableta 28 tableta 35 tableta 56 tableta 70 tableta
Following short term treatment (median duration 47 days), weight gain ≥ 7% of baseline body weight was very common (22.2 %), ≥ 15 % was common (4.2 %) and ≥ 25 % was uncommon (0.8 %). 
Nakon kratkotrajnog liječenja (medijan trajanja 47 dana), povećanje tjelesne težine ≥ 7% od početne tjelesne težine bilo je vrlo često (22,2%), povećanje ≥ 15% bilo je često (4,2%), a ≥ 25% bilo je manje često (0,8%).
Low-substituted hydroxypropylcellulose Aspartame 
Hidroksipropilceluloza, nisko supstituirana Aspartam
Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 
Prolazni asimptomatski porast razina aminotransferaz a jetre (ALT, AST), osobito na početku liječenja (vidjeti dio 4.4)
Zalasta orodispersible tablets are available in boxes of 14, 28, 35, 56 or 70 tablets in blisters (Alu/OPA/Alu/PVC). 
Zalasta raspadljive tablete za usta dostupne su u kutijama od 14, 28, 35, 56 ili 70 tableta u blisterima (Al/OPA/Al/PVC).
Each tablet contains 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg olanzapine. 
Svaka tableta sadrži 2,5 mg, 5 mg, 7,5 mg, 10 mg, 15 mg ili 20 mg olanzapina.
In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2 l/hr). 
U zdravih starijih ispitanika (65 godina i stariji) u odnosu na mlađe ispitanike prosječno poluvrijeme eliminacije bilo je produženo (51,8 u odnosu na 33,8 sati), a klirens je bio smanjen (17,5 u odnosu na 18,2 l/sat).
Following short term treatment (median duration 22 days), weight gain ≥ 7 % of baseline body weight (kg) was very common (40.6 %), ≥ 15 % of baseline body weight was common (7.1 %) and ≥ 25 % was common (2.5 %). 
Nakon kratkotrajnog liječenja (medijan trajanja 22 dana), povećanje tjelesne težine ≥ 7% od početne tjelesne težine (kg) bilo je vrlo često (40,6%), porast ≥ 15% od početne tjelesne težine bio je čest (7,1%), a ≥ 25% bio je čest (2,5%).
If you suffer from dementia, you or your carer/relative should tell your doctor if you have ever had a stroke or “mini” stroke. 
Ako bolujete od zaboravljivosti (demencije), a imali ste moždani udar ili “manji” moždani udar, Vi ili Vaš skrbnik/rođak morate o tome obavijestiti liječnika.
Nervous system disorders Somnolence 
Poremećaji živčanog sustava Pospanost
Each tablet contains 323.5 mg lactose. 
Svaka tableta sadrži 323,5 mg laktoze.
If you suffer from any of the following illnesses tell your doctor as soon as possible: ─ Stroke or “mini” stroke (temporary symptoms of stroke) ─ Parkinson's disease ─ Prostate problems ─ A blocked intestine (Paralytic ileus) ─ Liver or kidney disease ─ Blood disorders ─ Heart disease ─ Diabetes ─ Seizures ─ If you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets) 
Ako bolujete od bilo koje od sljedećih bolesti, obavijestite svojeg liječnika što je prije moguće: - Moždani udar ili “mali” moždani udar (kratkotrajni simptomi moždanog udara) - Parkinsonova bolest - Tegobe s prostatom - Zatvor crijeva (paralitički ileus) - Bolest jetre ili bubrega - Poremećaji krvi - Bolest srca - Šećerna bolest - Napadaji
Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking Zalasta and regularly during treatment. 
Prije početka uzimanja Zalaste te redovito tijekom liječenja, liječnik bi Vam trebao obaviti krvne pretrage kako bi provjerio razinu šećera i određenih masnoća u krvi.
Microcrystalline cellulose Crospovidone 
Celuloza, mikrokristalična Krospovidon
Adverse event identified from clinical trials in the Olanzapine Integrated Database. 
Nuspojava je identificirana iz kliničkih ispitivanja u integriranoj bazi podataka za olanzapin.
In female versus male subjects the mean elimination half life was somewhat prolonged (36.7 versus 32.3 hr) and the clearance was reduced (18.9 versus 27.3 l/hr). 
U žena je prosječno poluvrijeme eliminacije nešto duže u odnosu na muškarce (36,7 u odnosu na 32,3 sata), a klirens je smanjen (18,9 u odnosu na 27,3 l/sat).
• blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. 
osoba), posebno u nogama (simptomi uključuju oticanje, bol i crvenilo nogu), koji može putovati krvnim žilama do pluća uzrokujući bol u prsima i otežano disanje.
Rare side effects (may affect up to 1 in 1000 people) include lowering of normal body temperature; abnormal rhythms of the heart; sudden unexplained death; inflammation of the pancreas causing severe stomach pain, fever and sickness; liver disease appearing as yellowing of the skin and white parts of the eyes; muscle disease presenting as unexplained aches and pains; and prolonged and/or painful erection. 
Rijetke nuspojave (mogu se javiti u najviše 1 na 1000 osoba) uključuju sniženje normalne tjelesne temperature; poremećaj rada srca; naglu neobjašnjivu smrt; upalu gušterače koja uzrokuje jaku bol u trbuhu, vrućicu i mučninu; bolest jetre koja se očituje žutilom kože i bjeloočnica; bolest mišića koja se manifestira neobjašnjivim bolovima; te produžena i/ili bolna erekcija.
Each orodispersible tablet contains 5 mg, 7.5 mg, 10 mg, 15 mg or 20 mg olanzapine. 
Svaka raspadljiva tableta za usta sadrži 5 mg, 7,5 mg, 10 mg, 15 mg ili 20 mg olanzapina.
Musculoskeletal and connective tissue disorders Arthralgia 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva Artralgija
Urinary incontinence, urinary retention Urinary hesitation 
Poremećaji bubrega i mokraćnog sustava Urinarna inkontinencija, urinarna retencija
Zalasta 7.5 mg tablets Each tablet contains 121.3 mg lactose. 
Zalasta 7,5 mg tablete Svaka tableta sadrži 121,3 mg laktoze.
In non-smoking versus smoking subjects (males and females) the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7 l/hr). 
Prosječno poluvrijeme eliminacije u ispitanika nepušača (muškarci i žene) bilo je duže nego u ispitanika pušača (38,6 u odnosu na 30,4 sata), a klirens je bio manji (18,6 u odnosu na 27,7 l/sat).
orodispersible tablet 
raspadljiva tableta za usta
Patients gaining ≥ 7 %, ≥ 15 % and ≥ 25 % of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 %, 31.7 % and 12.3 % respectively). 
Tijekom dugotrajne izloženosti lijeku (najmanje 48 tjedana), povećanje tjelesne težine ≥ 7%, ≥ 15% i ≥ 25% od početne bilo je vrlo često (64,4%, 31,7%, odnosno 12,3%).
Seizures have been reported to occur uncommonly in patients when treated with olanzapine. 
Zabilježeno je da se konvulzije manje često pojavljuju u bolesnika liječenih olanzapinom.
Lactose monohydrate Powdered cellulose Pregelatinised maize starch Maize starch 
Kukuruzni škrob, prethodno geliran Kukuruzni škrob
There is a risk of feeling drowsy when you are given Zalasta. 
Tijekom uzimanja Zalaste postoji rizik da se osjećate pospano.
Zalasta 2.5 mg tablets Each tablet contains 40.4 mg lactose. 
Zalasta 2,5 mg tablete Svaka tableta sadrži 40,4 mg laktoze.
Gynaecomastia/breast enlargement in males 
Ginekomastija/po većanje dojki u muškaraca
Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth. 
Manje česte nuspojave (mogu se javiti u manje od 1 na 100 osoba) uključuju preosjetljivost (npr. oticanje u ustima i grlu, svrbež; osip); šećernu bolest ili pogoršanje šećerne bolesti, ponekad povezano s ketoacidozom (ketonima u krvi i mokraći) ili komom; napadaje, obično povezane s napadajima u povijesti bolesti (epilepsija); mišićnu ukočenost ili grč (uključujući pokrete očiju); sindrom nemirnih nogu; poteškoće s govorom; mucanje; usporeni rad srca; osjetljivost na sunčevu svjetlost; krvarenje iz nosa; nadimanje trbuha; gubitak pamćenja ili zaboravljivost; nemogućnost zadržavanja mokraće (inkontinencija); nemogućnost mokrenja; ispadanje kose; izostanak ili smanjenje menstruacija i promjene na grudima u muškaraca i žena, kao što je poremećaj stvaranja majčinog mlijeka ili abnormalan rast.
In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1%; a potential contributing factor could be high plasma valproate levels. 
U jednom kliničkom ispitivanju u bolesnika s bipolarnom manijom, kombinacijska terapija valproata i olanzapina uzrokovala je pojavu neutropenije od 4,1%.
Investigations Elevated plasma prolactin levels 
Povišene razine prolaktina u plazmi
─ High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Zalasta. 
- U bolesnika koji uzimaju Zalastu uočena je visoka razina šećera i masnoća u krvi (trigliceridi i kolesterol).
The mean increase in olanzapine AUC was 52% and 108% respectively. 
Prosječni porast AUC olanzapina iznosio je 52% u žena nepušača, odnosno 108% u muškaraca pušača.
Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment. 
Često je uočen prolazni asimptomatski porast vrijednosti jetrenih aminotransferaza, alanin transferaze (ALT) i aspartat transferaze (AST), osobito u ranoj fazi liječenja.
Zalasta 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg orodispersible tablets: available in boxes of 14, 28, 35, 56 and 70 tablets in blisters. 
Zalasta raspadljive tablete za usta od 5 mg, 7,5 mg, 10 mg, 15 mg i 20 mg: dostupne su u kutijama od 14, 28, 35, 56 i 70 tableta u blisterima.
Zalasta 20 mg tablets EU/1/07/415/027-031 
Zalasta 20 mg tablete EU/1/07/415/027-031
Colloidal anhydrous silica Magnesium stearate 
Silicijev dioksid, koloidni, bezvodni Magnezijev stearat
What Zalasta looks like and contents of the pack Zalasta 5 mg, 7.5 mg, 10 mg, 15 mg and 20 mg orodispersible tablets are: round, slightly biconvex, yellow marbled tablets with possible individual spots. 
Zalasta raspadljive tablete za usta od 5 mg, 7,5 mg, 10 mg, 15 mg i 20 mg su: okrugle, blago bikonveksne, žuto mramorirane tablete s mogućim pojedinačnim mrljama.
Other medicines and Zalasta 
Drugi lijekovi i Zalasta
Dizziness Akathisia Parkinsonism Dyskinesia 
Omaglica Akatizija Parkinsonizam Diskinezija
14 orodispersible tablets 28 orodispersible tablets 35 orodispersible tablets 56 orodispersible tablets 70 orodispersible tablets 
14 raspadljivih tableta za usta 28 raspadljivih tableta za usta 35 raspadljivih tableta za usta 56 raspadljivih tableta za usta 70 raspadljivih tableta za usta
Zalasta 10 mg tablets Each tablet contains 161.8 mg lactose. 
Svaka tableta sadrži 161,8 mg laktoze.
Zalasta 20 mg tablets 
Zalasta 20 mg tablete
This medicine contains 0.75 mg aspartame in each 7.5 mg orodispersible tablet. 
Ovaj lijek sadrži 0,75 mg aspartama u svakoj 7,5 mg raspadljivoj tableti za usta.
Drug withdrawal syndrome neonatal (see section 4.6) 
Sindrom ustezanja u novorođenčadi (vidjeti dio 4.6)
Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males. 
Česte nuspojave (mogu se javiti u manje od 1 na 10 osoba) uključuju promjene razina nekih krvnih stanica, cirkulirajućih masti u krvi te, u ranim fazama liječenja, privremena povećanja razine jetrenih enzima; povišene razine šećera u krvi i mokraći; povećanje razine mokraćne kiseline i kreatin fosfokinaze u krvi; pojačan apetit; omaglicu; nemir; nevoljno drhtanje; neuobičajene pokrete (diskinezije); zatvor; suha usta; osip; slabost; pojačani umor; zadržavanje vode u tijelu koje dovodi do otečenosti ruku, zglobova ili stopala te seksualni poremećaji kao što su smanjenje libida u muškaraca i žena ili erektilne disfunkcije u muškaraca.
Zalasta 15 mg tablets EU/1/07/415/022-026 
Zalasta 15 mg tablete EU/1/07/415/022-026
Vascular disorders Orthostatic hypotension 
Krvožilni poremećaji Ortostatska hipotenzija
Zalasta 7.5 mg tablets 
Zalasta 7,5 mg tablete
Zalasta 5 mg tablets EU/1/07/415/006-010 
Zalasta 5 mg tablete EU/1/07/415/006-010
If this happens after you have been given Zalasta tell your doctor. 
Vam se ovo pojavi nakon uzimanja Zalaste, obratite se svom liječniku.